Iterum Therapeutics Plc

Iterum Therapeutics Plc company information, Employees & Contact Information

Updated June 2026

Quick answer

Iterum Therapeutics Plc is a Pharmaceutical Manufacturing company and founded in 2015. It has approximately 20 employees on record. Contact data was last refreshed in June 2026. Find Iterum Therapeutics Plc's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.

Company Details

Employees
20
Founded
2015
Address
3 Dublin Landings North Wall Quay, Dublin,ireland 1,ireland
Phone
+353 1 903 8920
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Dublin, Ireland
Looking for a particular Iterum Therapeutics Plc employee's phone or email?

Iterum Therapeutics Plc Questions

News

Iterum Therapeutics Announces U.S. Commercial Launch of ORLYNVAHTM Targeted for Q4 2025 in Partnership with EVERSANA - Quiver Quantitative

Iterum Therapeutics Announces U.S. Commercial Launch of ORLYNVAHTM Targeted for Q4 2025 in Partnership with EVERSANA Quiver Quantitative

Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence - Urology Times

Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence Urology Times

Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History - Stock Titan

Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History Stock Titan

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - Yahoo Finance

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth Yahoo Finance

FDA approves oral sulopenem for uncomplicated urinary tract infection - Urology Times

FDA approves oral sulopenem for uncomplicated urinary tract infection Urology Times

Iterum Therapeutics Grants Share Option to Chief Commercial Officer Christine Coyne as Part of Employment Agreement - Quiver Quantitative

Iterum Therapeutics Grants Share Option to Chief Commercial Officer Christine Coyne as Part of Employment Agreement Quiver Quantitative

Novel Antibiotic Sulopenem Misses Primary End Point in cIAI Trial - Medical Professionals Reference

Novel Antibiotic Sulopenem Misses Primary End Point in cIAI Trial Medical Professionals Reference

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - Yahoo Finance

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. Yahoo Finance

FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI - Urology Times

FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI Urology Times

Top Iterum Therapeutics Plc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant